云顶新耀将向I-Mab公司投资3,090万美元(折合约2.426亿港元)。交易完成后,包括此前云顶新耀已持有的I-Mab股份在内,公司将合计持有I-Mab约16.1%的股份,成为I-Mab的第一大股东。I-Mab近期于2025年欧洲肿瘤内科学会胃肠道肿瘤大会(ESMO GI)上公布了Givastomig(Claudin 18.2 x 4-1BB双特异性抗体)联合免疫治疗用于一线胃癌治疗的1b期剂量...
Source Link云顶新耀将向I-Mab公司投资3,090万美元(折合约2.426亿港元)。交易完成后,包括此前云顶新耀已持有的I-Mab股份在内,公司将合计持有I-Mab约16.1%的股份,成为I-Mab的第一大股东。I-Mab近期于2025年欧洲肿瘤内科学会胃肠道肿瘤大会(ESMO GI)上公布了Givastomig(Claudin 18.2 x 4-1BB双特异性抗体)联合免疫治疗用于一线胃癌治疗的1b期剂量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.